Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 7.08% is 500% above its 5-year average of -1.77%, near the high end of its 5-year range (-6.30%–7.08%).
254.00% above its 12-month average of 2.00%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 1.65%.
RETURN ON ASSETS (ROA)
7.08%
RETURN ON ASSETS (ROA) AVG TTM
2.00%
RETURN ON ASSETS (ROA) AVG 3Y
-0.05%
RETURN ON ASSETS (ROA) AVG 5Y
-1.77%
RETURN ON ASSETS (ROA) AVG 10Y
0.06%
RETURN ON ASSETS (ROA) AVG 15Y
0.94%
RETURN ON ASSETS (ROA) AVG 20Y
-27.94%
CURRENT VS TTM AVG
+254.00%
CURRENT VS 3Y AVG
+12972.73%
CURRENT VS 5Y AVG
+499.62%
CURRENT VS 10Y AVG
+11881.54%
CURRENT VS 15Y AVG
+652.58%
CURRENT VS 20Y AVG
+125.34%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+121.96%
vs the sector median at left
ANI Pharmaceuticals, Inc.
Market Cap
$1.62B
Return on Assets (ROA)
7.08%
TTM Avg
2.00%
3Y Avg
-0.05%
5Y Avg
-1.77%
Market Cap
$1.62B
Return on Assets (ROA)
-4.28%
TTM Avg
-11.96%
3Y Avg
-5.19%
5Y Avg
-5.19%
Market Cap
$1.62B
Return on Assets (ROA)
-13.91%
TTM Avg
-19.51%
3Y Avg
-22.81%
5Y Avg
-24.34%
Market Cap
$1.60B
Return on Assets (ROA)
-44.90%
TTM Avg
-37.58%
3Y Avg
-38.70%
5Y Avg
-36.23%
Market Cap
$1.60B
Return on Assets (ROA)
-25.60%
TTM Avg
-33.58%
3Y Avg
-30.56%
5Y Avg
-19.71%
Market Cap
$1.59B
Return on Assets (ROA)
-43.15%
TTM Avg
-37.60%
3Y Avg
-124.49%
5Y Avg
-99.59%
Market Cap
$1.60B
Return on Assets (ROA)
1.96%
TTM Avg
0.34%
3Y Avg
0.01%
5Y Avg
0.90%
Market Cap
$1.68B
Return on Assets (ROA)
-69.03%
TTM Avg
-70.44%
3Y Avg
-88.82%
5Y Avg
-88.82%
Market Cap
$1.56B
Return on Assets (ROA)
-52.77%
TTM Avg
-17.21%
3Y Avg
-29.94%
5Y Avg
-28.87%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ANI Pharmaceuticals, Inc. (ANIP) | $1.62B | 7.08% | 2.00% | -0.05% | -1.77% |
| Septerna Inc (SEPN)vs › | $1.62B | -4.28% | -11.96% | -5.19% | -5.19% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | -13.91% | -19.51% | -22.81% | -24.34% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.60B | -44.90% | -37.58% | -38.70% | -36.23% |
| uniQure N.V. (QURE)vs › | $1.60B | -25.60% | -33.58% | -30.56% | -19.71% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -43.15% | -37.60% | -124.49% | -99.59% |
| Omnicell, Inc. (OMCL)vs › | $1.60B | 1.96% | 0.34% | 0.01% | 0.90% |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.68B | -69.03% | -70.44% | -88.82% | -88.82% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.56B | -52.77% | -17.21% | -29.94% | -28.87% |
| Personalis, Inc. (PSNL)vs › | $1.70B | -34.34% | -27.20% | -35.30% | -29.09% |
ROA
7.1%
ROE
17.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 5.44% |
| 2024-12-31 | -1.44% |
| 2023-12-31 | 2.08% |
| 2022-12-31 | -6.30% |
| 2021-12-31 | -5.52% |
| 2020-12-31 | -4.89% |
| 2019-12-31 | 1.33% |
| 2018-12-31 | 3.60% |
| 2017-12-31 | -0.26% |
| 2016-12-31 | 1.22% |
| 2015-12-31 | 5.39% |
| 2014-12-31 | 10.90% |
| 2013-12-31 | 0.68% |
| 2012-12-31 | -71.49% |
| 2011-12-31 | -82.73% |
| 2010-12-31 | -103.19% |
| 2009-12-31 | -130.44% |
| 2008-12-31 | -98.56% |
| 2007-12-31 | -24.28% |
| 2006-12-31 | 12.48% |
| 2005-12-31 | -100.80% |
| 2004-12-31 | -67.40% |
| 2003-12-31 | -62.30% |
| 2002-12-31 | -64.81% |
| 2001-12-31 | -52.44% |
| 2000-12-31 | -112.07% |
| 1999-12-31 | -24.33% |
| 1998-12-31 | -77.10% |
